Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Galapagos and LEO Pharma Collaborate on Antibacterial Research

  • BioFocus, Galapagos' service division, will use a subset of its natural compound collection for high-throughput screening, hit verification, and profiling of selected compounds for LEO Pharma's antibacterial research program. This collaboration marks Galapagos' first for its natural compound collection.

    Galapagos stands to receive up to EUR 400,000 in project fees and up to EUR 3 million in milestone payments. The company may also receive royalties on sales of commercial products resulting from the collaboration. 

    BioFocus says its natural compound collections are based on bacterial and fungal sources, offering characteristics differentiating these from synthetic chemistry collections, including high chemical and functional diversity, potent pharmacological activities over a broad range of biological targets, and desirable physicochemical properties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »